The FDA granted fast-track status to Cubist Pharmaceuticals' late-stage antibiotic CXA-201, a combination of ceftolozane and tazobactam, as a treatment for hospital-acquired bacterial pneumonia and complicated urinary tract infections. The antibiotic, which already received a fast-track designation for complicated intra-abdominal infections, is in two Phase III trials for the urinary and abdominal indications. Cubist plans to initiate another late-stage trial against ventilator-associated pneumonia in the coming months.
Cubist gets fast-track status in 2 areas for antibiotic combo
SmartBrief Job Listings for Health Care
|Chief Operating Officer||
Presence Health Partners
|Des Plaines, IL|
|Sr. Business Systems Analyst||
|Sr. Reimbursement Analyst||
Olympus America Inc.
|Staff VP Medical Policy Development-81321||